Compare Amgen, Inc. (AMGN) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Growth Index Fund ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while Vanguard Growth Index Fund ETF trades at $89. The key difference: Amgen, Inc. pays a 2.42% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals.
| AMGN | VUG | |
|---|---|---|
Market Cap | $225.71B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $90.29 |
52-Week Low | $271.18 | $70.00 |
Enterprise Value | $269.02B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vanguard Growth ETF (VUG) trades at $89.4, up 0.81% today, with a bullish technical signal driven by strong moving average support. Recent news highlights significant institutional buying interest, with multiple firms increasing stakes by over 500% in Q2 2026. The ETF focuses on large-cap growth stocks, offering broad exposure to innovative US companies.
Outlook remains positive given institutional accumulation and growth stock momentum, though an RSI of 95.06 on a 6-day basis indicates potential overbought conditions. Key risks include market volatility and sensitivity to interest rate changes, but long-term growth prospects appear solid based on historical performance and sector trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
